Clinical trials: Borderline Resectable
Pancreatic Adenocarcinoma
A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma
This is a phase II, single arm, non-randomized, open label study of liposomal irinotecan with FOLFOX in the neoadjuvant setting in patients with resectable or borderline resectable, previously untreated pancreatic adenocarcinoma.
- Trial name
- NCT03483038
- Testing
- Liposomal Irinotecan, FOLFOX regimen
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Florida
Adenocarcinoma of Pancreas
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year.
- Trial name
- NCT01359007
- Testing
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Oklahoma
Pancreatic Cancer
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation…
- Trial name
- NCT03161379
- Testing
- Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer. Patients with BRPC have tumors in close contact with the vasculature but not to the extent that resection is prohibited.
- Trial name
- NCT03099265
- Testing
- neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Pancreatic Adenocarcinoma
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling).
- Trial name
- NCT01726582
- Testing
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 229 people
- Sponsor
- Medical College of Wisconsin
Borderline Resectable Pancreatic Cancer
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and…
- Trial name
- NCT02241551
- Testing
- gemcitabine/nab-paclitaxel, mFOLFIRINOX
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Nathan Bahary, MD
Histologically or Cytologically Confirmed Pancreatic Ca, Unresectable or Borderline Resectable Pancreatic Ca
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Background: Pancreatic cancer is difficult to treat because by the time most cases are diagnosed, the tumors are too large to be removed surgically.
- Trial name
- NCT01294358
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC.
- Trial name
- FAPI-46 PDAC (NCT05262855)
- Testing
- [68Ga]FAPI-46
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- SOFIE
Pancreas Neoplasm Malignant Resectable
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
- Trial name
- NCT02243358
- Testing
- Folfox6, Gemcitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Henry Ford Health System
Pancreatic Adenocarcinoma
Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
To assess if percentage change in 18F-FLT PET/CT quantitative parameters (SUV max, or SUV peak or proliferative tumor volume) after 2 cycles of neoadjuvant chemotherapy can predict overall survival at 1 and 2 years and…
- Trial name
- NCT03318497
- Testing
- 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Texas Southwestern Medical Center
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
- Conditions
- Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04669197
- Testing
- Paclitaxel protein bound, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Neoplasms
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at the patient's tumor followed by more…
- Trial name
- NCT00833859
- Testing
- GTX (gemcitabine, docetaxel and capecitabine), stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer
This randomized phase II trial studies how well combination chemotherapy (mFOLFIRINOX) with or without hypofractionated radiation therapy before surgery works in patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT02839343
- Testing
- radiation therapy, surgery, mFOLFIRINOX
- Where
- 155 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- Alliance for Clinical Trials in Oncology